Morbus Crohn der DGVS

1142
Leitlinie
444 Korelitz BI, Adler DJ, Mendelsohn RA et al. Long-term experience with
6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol
1993; 88: 1198–1205
445 Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of
fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340:
1398–1405
446 Sands BE, Blank MA, Patel K et al. Long-term treatment of rectovaginal
fistulas in Crohn’s disease: response to infliximab in the ACCENT
II Study. Clin Gastroenterol Hepatol 2004; 2: 912–920
447 Lichtenstein GR, Yan S, Bala M et al. Infliximab maintenance treatment
reduces hospitalizations, surgeries, and procedures in fistulizing
Crohn’s disease. Gastroenterology 2005; 128: 862–869
448 Farrell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab
therapy in 100 patients with Crohn’s disease. Am J Gastroenterol
2000; 95: 3490–3497
449 Ricart E, Panaccione R, Loftus EV et al. Infliximab for Crohn’s disease
in clinical practice at the Mayo Clinic: the first 100 patients. Am J
Gastroenterol 2001; 96: 722–729
450 Sandborn WJ. A critical review of cyclosporine therapy in inflammatoy
bowel disease. Inflamm Bowel Dis 1995; 1: 48–63
451 Sandborn WJ. Preliminary report on the use of oral tacrolimus
(FK506) in the treatment of complicated proximal small bowel and
fistulizing Crohn’s disease. Am J Gastroenterol 1997; 92: 876–879
452 Fellermann K, Ludwig D, Stahl M et al. Steroid-unresponsive acute attacks
of inflammatory bowel disease: immunomodulation by tacrolimus
(FK506). Am J Gastroenterol 1998; 93: 1860–1866
453 Lowry PW, Weaver AL, Tremaine WJ et al. Combination therapy with
oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for
treatment-refractory Crohn’s disease perianal fistulae. Inflamm Bowel
Dis 1999; 5: 239–245
454 Ierardi E, Principi M, Francavilla R et al. Oral tacrolimus long-term
therapy in patients with Crohn’s disease and steroid resistance. Aliment
Pharmacol Ther 2001; 15: 371–377
455 Sandborn WJ, Present DH, Isaacs KL et al. Tacrolimus for the treatment
of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled
trial. Gastroenterology 2003; 125: 380–388
456 Wenzl HH, Hinterleitner TA, Aichbichler BW et al. Mycophenolate mofetil
for Crohn’s disease: short-term efficacy and long-term outcome.
Aliment Pharmacol Ther 2004; 19: 427–434
457 Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients
with refractory Crohn’s disease: an open-label trial. Gastroenterology
1999; 117: 1271–1277
458 Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot
study of low-dose thalidomide in chronically active, steroid-dependent
Crohn’s disease. Gastroenterology 1999; 117: 1278–1287
459 Colombel JF, Mathieu D, Bouault JM et al. Hyperbaric oxygenation in
severe perineal Crohn’s disease. Dis Colon Rectum 1995; 38:
609–614
460 Vaughan D, Drumm B. Treatment of fistulas with granulocyte colonystimulating
factor in a patient with Crohn’s disease. N Engl J Med
1999; 340: 239–240
461 Levy C, Tremaine WJ. Management of internal fistulas in Crohn’s
disease. Inflamm Bowel Dis 2002; 8: 106–111
462 Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications
of Crohn’s disease and ulcerative colitis: a study of 700 patients.
Medicine (Baltimore) 1976; 55: 401–412
463 Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy
Study Group preliminary criteria for the classification of
spondylarthropathy. Arthritis Rheum 1991; 34: 1218–1227
464 Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory
bowel disease: their articular distribution and natural
history. Gut 1998; 42: 387–391
465 de Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated
in inflammatory bowel disease: prevalence and HLA association.
J Rheumatol 2000; 27: 2860–2865
466 Gran JT, Husby G. Joint manifestations in gastrointestinal diseases. 1.
Pathophysiological aspects, ulcerative colitis and Crohn’s disease.
Dig Dis 1992; 10: 274–294
467 Protzer U, Duchmann R, Hohler T et al. Enteropathic spondylarthritis
in chronic inflammatory bowel diseases: prevalence, manifestation
pattern and HLA association. Med Klin 1996; 91: 330–335
468 Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies
in HLA-B27 positive and negative blood donors. Arthritis
Rheum 1998; 41: 58–67
469 El Miedany Y, Youssef S, Ahmed I et al. The gastrointestinal safety and
effect on disease activity of etoricoxib, a selective cox-2 inhibitor in
inflammatory bowel diseases. Am J Gastroenterol 2006; 101:
311–317
470 Sandborn WJ, Stenson WF, Brynskov J et al. Safety of celecoxib in patients
with ulcerative colitis in remission: a randomized, placebocontrolled,
pilot study. Clin Gastroenterol Hepatol 2006; 4: 203–211
471 Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis
with infliximab: a randomised controlled multicentre trial.
Lancet 2002; 359: 1187–1193
472 Generini S, Giacomelli R, Fedi R et al. Infliximab in spondyloarthropathy
associated with Crohn’s disease: an open study on the efficacy of
inducing and maintaining remission of musculoskeletal and gut manifestations.
Ann Rheum Dis 2004; 63: 1664–1669
473 Herfarth H, Obermeier F, Andus T et al. Improvement of arthritis and
arthralgia after treatment with infliximab (Remicade) in a German
prospective, open-label, multicenter trial in refractory Crohn’s disease.
Am J Gastroenterol 2002; 97: 2688–2690
474 Kaufman I, Caspi D, Yeshurun D et al. The effect of infliximab on extraintestinal
manifestations of Crohn’s disease. Rheumatol Int 2005;
25: 406–410
475 Rispo A, Scarpa R, Di Girolamo E et al. Infliximab in the treatment of
extra-intestinal manifestations of Crohn’s disease. Scand J Rheumatol
2005; 34: 387–391
476 Erlichman M, Holohan TV. Bone densitometry: patients receiving prolonged
steroid therapy. Health Technol Assess (Rockv) 1996: i–31
477 Ahmed SF, Horrocks IA, Patterson T et al. Bone mineral assessment by
dual energy X-ray absorptiometry in children with inflammatory bowel
disease: evaluation by age or bone area. J Pediatr Gastroenterol
Nutr 2004; 38: 276–280
478 Burnham JM, Shults J, Semeao E et al. Whole body BMC in pediatric
Crohn disease: independent effects of altered growth, maturation,
and body composition. J Bone Miner Res 2004; 19: 1961–1968
479 Fewtrell MS. Bone densitometry in children assessed by dual ” ray absorptiometry:
uses and pitfalls. Arch Dis Child 2003; 88: 795–798
480 von Tirpitz C, Klaus J, Steinkamp M et al. Therapy of osteoporosis in
patients with Crohn’s disease: a randomized study comparing sodium
fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17:
807–816
481 Compston JE. Emerging consensus on prevention and treatment of
glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2007; 9:
78–84
482 Bartram SA, Peaston RT, Rawlings DJ et al. A randomized controlled
trial of calcium with vitamin D, alone or in combination with intravenous
pamidronate, for the treatment of low bone mineral density
associated with Crohn’s disease. Aliment Pharmacol Ther 2003; 18:
1121–1127
483 Siffledeen JS, Fedorak RN, Siminoski K et al. Randomized trial of etidronate
plus calcium and vitamin D for treatment of low bone mineral
density in Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3:
122–132
484 Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med
Surg 2007; 26: 114–125
485 Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders.
Part II. J Am Acad Dermatol 1992; 26: 371–383
486 Kirsch B et al. Dermatosen bei chronisch entzündlichen Darmerkrankungen.
Ergebnisse einer Untersuchung von 119 Morbus Crohn/C.
ulcerosa-Patienten. Akt Dermatol 1992; 18: 17–22
487 Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001;
68: 287–297
488 Juillerat P, Mottet C, Froehlich F et al. Extraintestinal manifestations of
Crohn’s disease. Digestion 2005; 71: 31–36
489 Requena L, Requena C. Erythema nodosum. Dermatol Online J 2002;
8: 4
490 Matis WL, Ellis CN, Griffiths CE et al. Treatment of pyoderma gangrenosum
with cyclosporine. Arch Dermatol 1992; 128: 1060–1064
491 Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus
in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999;
140: 564–565
492 Brooklyn TN, Dunnill MG, Shetty A et al. Infliximab for the treatment
of pyoderma gangrenosum: a randomised, double blind, placebo
controlled trial. Gut 2006; 55: 505–509
493 Mintz R, Feller ER, Bahr RL et al. Ocular manifestations of inflammatory
bowel disease. Inflamm Bowel Dis 2004; 10: 135–139
Hoffmann JC et al. Diagnostik und Therapie… Z Gastroenterol 2008; 46: 1094–1146